The Diabetic Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Neuropathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued products.

GlobalData tracks 53 drugs in development for Diabetic Neuropathy by 44 companies/universities/institutes. The top development phase for Diabetic Neuropathy is preclinical with 24 drugs in that stage. The Diabetic Neuropathy pipeline has 51 drugs in development by companies and two by universities/ institutes. Some of the companies in the Diabetic Neuropathy pipeline products market are: Praetego, Omeros and Korea United Pharm.

The key targets in the Diabetic Neuropathy pipeline products market include Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), and Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1).

The key mechanisms of action in the Diabetic Neuropathy pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with three drugs in Phase II. The Diabetic Neuropathy pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Diabetic Neuropathy pipeline products market including Small Molecule, and Monoclonal Antibody.

Diabetic Neuropathy overview

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain. Predisposing factors include obesity, hypertension, high lipid and sugar levels, and smoking. It may be managed by medication and dietary modification.

For a complete picture of Diabetic Neuropathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.